201 related articles for article (PubMed ID: 22365247)
1. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment.
Maher TM
Clin Chest Med; 2012 Mar; 33(1):69-83. PubMed ID: 22365247
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapeutic interventions for idiopathic pulmonary fibrosis.
Chakraborty S; Chopra P; Ambi SV; Dastidar SG; Ray A
Expert Opin Investig Drugs; 2014 Jul; 23(7):893-910. PubMed ID: 24766571
[TBL] [Abstract][Full Text] [Related]
3. The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis.
Saito A; Horie M; Micke P; Nagase T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30445777
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targets in idiopathic pulmonary fibrosis.
Kolb M; Bonella F; Wollin L
Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast.
Gharaee-Kermani M; Hu B; Phan SH; Gyetko MR
Curr Med Chem; 2009; 16(11):1400-17. PubMed ID: 19355895
[TBL] [Abstract][Full Text] [Related]
6. Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules.
Lv M; Liu Y; Ma S; Yu Z
Future Med Chem; 2019 Oct; 11(19):2595-2620. PubMed ID: 31633402
[TBL] [Abstract][Full Text] [Related]
7. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.
Oruqaj G; Karnati S; Vijayan V; Kotarkonda LK; Boateng E; Zhang W; Ruppert C; Günther A; Shi W; Baumgart-Vogt E
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):E2048-57. PubMed ID: 25848047
[TBL] [Abstract][Full Text] [Related]
8. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
Moodley Y; Corte T; Richeldi L; King TE
Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967
[TBL] [Abstract][Full Text] [Related]
9. The hedgehog system machinery controls transforming growth factor-β-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis.
Cigna N; Farrokhi Moshai E; Brayer S; Marchal-Somme J; Wémeau-Stervinou L; Fabre A; Mal H; Lesèche G; Dehoux M; Soler P; Crestani B; Mailleux AA
Am J Pathol; 2012 Dec; 181(6):2126-37. PubMed ID: 23031257
[TBL] [Abstract][Full Text] [Related]
10. Redox Imbalance in Idiopathic Pulmonary Fibrosis: A Role for Oxidant Cross-Talk Between NADPH Oxidase Enzymes and Mitochondria.
Veith C; Boots AW; Idris M; van Schooten FJ; van der Vliet A
Antioxid Redox Signal; 2019 Nov; 31(14):1092-1115. PubMed ID: 30793932
[No Abstract] [Full Text] [Related]
11. Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets.
Liu YM; Nepali K; Liou JP
J Med Chem; 2017 Jan; 60(2):527-553. PubMed ID: 28122457
[TBL] [Abstract][Full Text] [Related]
12. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis.
Zhang L; Li Y; Liang C; Yang W
Int J Mol Med; 2014 Feb; 33(2):478-86. PubMed ID: 24276150
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic pulmonary fibrosis (IPF) signaling pathways and protective roles of melatonin.
Hosseinzadeh A; Javad-Moosavi SA; Reiter RJ; Hemati K; Ghaznavi H; Mehrzadi S
Life Sci; 2018 May; 201():17-29. PubMed ID: 29567077
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targets and early stage clinical trials for pulmonary fibrosis.
Sato S; Yanagihara T; Kolb MRJ
Expert Opin Investig Drugs; 2019 Jan; 28(1):19-28. PubMed ID: 30513000
[TBL] [Abstract][Full Text] [Related]
15. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
[TBL] [Abstract][Full Text] [Related]
16. Pirfenidone in idiopathic pulmonary fibrosis.
Maher TM
Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
[TBL] [Abstract][Full Text] [Related]
17. Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications.
Nair GB; Matela A; Kurbanov D; Raghu G
Expert Rev Respir Med; 2016 Jun; 10(6):699-711. PubMed ID: 27094006
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review.
Fois AG; Paliogiannis P; Sotgia S; Mangoni AA; Zinellu E; Pirina P; Carru C; Zinellu A
Respir Res; 2018 Mar; 19(1):51. PubMed ID: 29587761
[TBL] [Abstract][Full Text] [Related]
19. Existing and emerging treatments for idiopathic pulmonary fibrosis.
Kolilekas L; Papiris S; Bouros D
Expert Rev Respir Med; 2019 Mar; 13(3):229-239. PubMed ID: 30632421
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of idiopathic pulmonary fibrosis.
Sergew A; Brown KK
Expert Opin Emerg Drugs; 2015; 20(4):537-52. PubMed ID: 26629731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
